Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode

The International Journal of Neuropsychopharmacology
S PridmoreMazena Rybak

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is a new technology which holds promise as a treatment of psychiatric disorders. Most work to date has been on depression. Superiority to placebo has been indicated in three small blind studies. We compared the antidepressant effects of rTMS and ECT in 32 patients suffering major depressive episode (MDE) who had failed to respond to at least one course of medication. There was no limit to the number of treatment sessions which could be given and treatment was continued until remission occurred or response plateaued. A significant main effect for treatment type was found [Pillai trace = 0.248, F(3,28) = 3.076, p = 0.044; power = 0.656], reflecting an advantage for ECT patients on measures of depression overall, however, rTMS produced comparable results on a number of measures. Blind raters using the 17-item Hamilton Depression Rating Scale (HDRS) found the rate of remission (HDRS = ? 8) was the same (68.8%), and the percentage improvement over the course of treatment of 55.6% (rTMS) and 66.4% (ECT), while favouring ECT, was not significantly different. Significant differences were shown (p & 0.03) in percentage improvement on Beck Depression Inventory ratings (rTMS, 45.5%; ECT,...Continue Reading

Citations

Mar 31, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·A ConcaA Hausmann
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Paul E Holtzheimer, Charles B Nemeroff
Dec 5, 2000·Journal of the Neurological Sciences·S Pridmore, G Oberoi
Jul 19, 2001·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·E M Wassermann, S H Lisanby
Feb 18, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Paul Fitzgerald
May 11, 2006·The Australian and New Zealand Journal of Psychiatry·Philip B Mitchell, Colleen K Loo
Aug 17, 2006·The Australian and New Zealand Journal of Psychiatry·Yvonne Turnier-SheaSaxby Pridmore
Aug 17, 2006·The Australian and New Zealand Journal of Psychiatry·Paul B FitzgeraldJayashri Kulkarni
Sep 22, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Saxby PridmoreMark George
Aug 21, 2012·Biology of Mood & Anxiety Disorders·Cristina Cusin, Darin D Dougherty
Nov 3, 2011·The Australian and New Zealand Journal of Psychiatry·Paul B Fitzgerald
Feb 22, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Juanjuan RenPaolo Maria Rossini
Oct 28, 2010·Expert Review of Neurotherapeutics·Mark S George
Dec 23, 2003·International Journal of Mental Health Nursing·Saxby PridmoreMark S George
Aug 16, 2008·The Mount Sinai Journal of Medicine, New York·Dani DumitriuSanjay J Mathew
Oct 19, 2006·Neurophysiologie clinique = Clinical neurophysiology·A Maertens de Noordhout
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Paul E Holtzheimer, Charles B Nemeroff
Jul 19, 2014·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Jean-Pascal LefaucheurLuis Garcia-Larrea
Jun 24, 2008·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Paul Fitzgerald
Aug 16, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Wim Simons, Michel Dierick
Nov 19, 2002·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·Sarah H LisanbyMichael J Crupain
Jun 22, 2002·The Cochrane Database of Systematic Reviews·J L MartinA Gironell
Nov 17, 2017·Neuromodulation : Journal of the International Neuromodulation Society·Ying Jiao ZhaoYee Ming Mok
Nov 5, 2002·Human Psychopharmacology·Leon GrunhausPinhas N Dannon
Jun 1, 2006·Neuropsychiatric Disease and Treatment·Gin S MalhiPerminder Sachdev
Feb 19, 2008·Current Opinion in Psychiatry·Paul B Fitzgerald, Zafiris J Daskalakis

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.